Kura Oncology Chairman and CEO Acquires Additional Company Shares
Kura Oncology CEO Troy Wilson purchased 100,000 shares at a $12.39 weighted average price. This follows a similar buy one week earlier, increasing his direct and trust holdings.
/ 5 items
#KURA↓
Kura Oncology Insider Buy: CEO Adds $1.11M Stake as Cash Runway Stretches to 2028
Kura Oncology CEO Troy Wilson bought 100K shares for $1.11M on Aug 17, 2026. Open-market buy follows KOMZIFTI sales and cash runway to 2028.
Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
FDA Approves Kura's Ziftomenib (Komzifti) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible NPM1 Mutation
The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.
Kura Oncology Shares Jump 6% After $30M Milestone Payment for Cancer Drug Trial
Kura Oncology stock rises 6% in premarket trading after receiving $30 million milestone payment from Kyowa Kirin for Phase 3 cancer drug trial advancement.